Charles Raine, MD
Endocrinology, Diabetes & Metabolism · Orangeburg, SCNPI 1255393211
Payments from drug & device makers
What this record shows
Sanofi-aventis U.S. LLC accounts for 61.4% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2020 at $2,154 and has fallen 93.3% since, to $144 in 2025.
Across 83 payments — averaging $43.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$2K
- Insulet Corporation$540
- Lilly USA, LLC$285
- Corcept Therapeutics$136
- Mannkind Corporation$119
- Valeritas, Inc.$101
- plus $222 from 9 others
What the payments were for
- Speaking & faculty fees$1,99455%
- Food & beverage$1,64245%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 15 | $2,233 |
| Insulet Corporation | 15 | $540 |
| Lilly USA, LLC | 16 | $285 |
| Corcept Therapeutics | 7 | $136 |
| Mannkind Corporation | 8 | $119 |
| Valeritas, Inc. | 7 | $101 |
| Xeris Pharmaceuticals, Inc. | 3 | $46 |
| Boehringer Ingelheim | 2 | $41 |
| Merck | 3 | $38 |
| Medtronic | 2 | $28 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Lifescan, Inc. | 1 | $16 |
| Novo Nordisk | 1 | $14 |
| Pfizer | 1 | $14 |
| Cequr Corporation | 1 | $10 |
How this compares
$3,635 in reported general payments places this provider in the 55th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.
See all endocrinology, diabetes & metabolism providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 84 | $115,267 |
| TrulicityDulaglutide | 104 | $111,505 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 88 | $89,325 |
| OzempicSemaglutide | 62 | $72,808 |
| JardianceEmpagliflozin | 61 | $64,686 |
| FarxigaDapagliflozin Propanediol | 92 | $57,251 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 67 | $45,499 |
| JanuviaSitagliptin Phosphate | 45 | $40,647 |
| RybelsusSemaglutide | 42 | $37,733 |
| Humalog Kwikpen U-200Insulin Lispro | 32 | $30,344 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 36 | $29,424 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 36 | $27,940 |
| JanumetSitagliptin Phos/Metformin Hcl | 21 | $19,362 |
| Lyumjev Kwikpen U-200Insulin Lispro-Aabc | 16 | $16,865 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 22 | $16,744 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog | $285 | $257,510269 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $14 | $115,793130 claims |
| MerckJanuvia, Janumet Xr, Janumet | $38 | $87,948102 claims |
| Boehringer IngelheimJardiance, Synjardy, Tradjenta | $41 | $87,49195 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.
Other endocrinology, diabetes & metabolism in Orangeburg
- Gauri DhirMyrtle Beach$417K
- Cory WhiteGreenville$413K
- Louis HaenelCharleston$377K
- Vonda CalcuttWalterboro$368K
- Ray VaughtersAiken$321K
- Donald EagertonMyrtle Beach$284K
- Beatrice HullCharleston$214K
- Joseph MathewsSummerville$168K
- Brittany HendersonMount Pleasant$157K
- Zouhair BibiConway$120K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.